One of the primary challenges facing Novo Nordisk is managing supply constraints ... These tools provide a clearer picture of investment opportunities, enabling more informed decisions about ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

"In order to secure supply chain readiness, Novo Nordisk now expects to file for the first regulatory approval of CagriSema during the first quarter of 2026," The Danish company said in its full-year.